Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 2/2016

01-02-2016 | Antiphospholipid Syndrome (S Zuily, Section Editor)

Organ Damage and Quality of Life in Antiphospholipid Syndrome

Authors: P. Alba, J. A. Gómez-Puerta, M. V. Goycochea-Robles, M. C. Amigo

Published in: Current Rheumatology Reports | Issue 2/2016

Login to get access

Abstract

Antiphospholipid syndrome (APS) affects young patients in the most productive years of their life, and the consequences of organic or tissue damage involve a decrease in health-related quality of life (HRQoL). While acute disease manifestations of APS are well known, information on the long-term prognosis and damage in affected patients is still very limited. Systemic lupus erythematosus (SLE) patients would be expected to experience long-term complications and even die as a consequence of APS. Organ damage in APS has been evaluated using different methods and definitions, including the SLICC/ACR Damage Index (SDI), which tend to underestimate aPL-related damage. A new damage index in APS has been proposed (DIAPS), and it seems to be more accurate than SDI. Given the implications for morbidity and mortality, it is imperative to assess accurately aPL-related damage and HRQoL in patients with APS.
Literature
1.
Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus. 2000;9:322–7.CrossRefPubMed
2.
Fischer-Betz R, Schneider M. Connective tissue diseases: evaluation of clinical response. Rheumatology (Oxford). 2008;47(2):234–5.
3.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed
4.
Merashli M, Hassan M, Noureldine A, et al. Antiphospholipid syndrome: an update. Eur J Clin Invest. 2015;45:653–62.CrossRefPubMed
5.
Amigo MC. What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? Lupus. 2014;23:1259–61.CrossRefPubMed
6.
Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303–8.CrossRefPubMed
7.
Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–12.PubMed
8.
9.
Sharma P, Scotland G, Cruickshank M, Tassie E, Fraser C, Burton C, Croal B, Ramsay CR, Brazzelli M. Is self.monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open 2015 (6): e007758.
10.
Gladman DD, Urowitz MB, Goldsmith CH, Bacon P, Fortin P, Ginzler E, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13.CrossRefPubMed
11.
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27:373–6.PubMed
12.
Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10:93–6.CrossRefPubMed
13.
Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol. 2002;29:1398–400.PubMed
14.
Cardoso CR, Signorelli FV, Papi JA, Salles GF. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus. 2008;17:1042–8.CrossRefPubMed
15.
Goncalves MJ, Sousa S, Inès LS, et al. Characterization of damage in Portuguese lupus patients: analysis of a National Lupus Registry. Lupus. 2015;24:256–62.CrossRefPubMed
16.
Ruiz Irastorza G, Egurbide MV, Martinez-Berriotxoa A, et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus. 2004;13:900–5.CrossRefPubMed
17.
Ruiz Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164:77–82.CrossRefPubMed
18.•
Cervera R, Serrano R, Pons-Estel GJ, on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies), et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011–8. An important paper describing a series of 1000 European APS patients with a long term follow-up.CrossRefPubMed
19.•
Grika EP, Ziakas PD, Zintzaras E, et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012;39:516–23. This study describes morbidity, organ damage, and cause of death in Greek patients with APS after a long-term follow-up.CrossRefPubMed
20.
Barbhaiya M, Erkan D, Rodriguez-Alamraz E, Ramón G, Vega J, Lockshin MD. Utility of the Systemic Lupus International Collaborating Clinics (SLICC) American College of Rheumatology (ACR) Damage Indexfor antiphospholipid antibody (aPL) positive patients. Arthritis Rheum. 2011;63:Suppl:S3.
21.••
Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015;24:927–34. This paper is of importance as it describes for the first time, the development of a specific damage index for thrombotic APS.CrossRefPubMed
22.
23.
Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary sntiphospholipid syndrome: functional outcome after 10 years. J Rheumatol. 2000;27:2817–21.PubMed
24.
Dall’Ara F, Reggia R, Taraborelli M, Andreoli L, Taglietti M, Frassi M, et al. Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus. 2014;23:1255–8.CrossRefPubMed
25.
Tektonidou MG, Ioannidis JP, Boki KA, et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000;93:523–30.CrossRefPubMed
26.
Ugolini Lopes M, Aguila L, Tonon R et al. SLICC and DIAPS. Potential indices for damage assessment in primary antiphospholipid syndrome (PAPS). Presented at APLA & LACA 2013, 14th International Congress on Antiphospholipid Antibodies. 18–21 September 2013. Rio de Janeiro, Brazil.
27.
Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.CrossRefPubMed
28.
Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2003;5:395–400.CrossRefPubMed
29.
Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore). 1998;77:195–207.CrossRef
30.
Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730–6.CrossRefPubMedPubMedCentral
31.
Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis. 2007;66:740–6.CrossRefPubMedPubMedCentral
32.
Cervera R, Bucciarelli S, Plasin MA, Gómez-Puerta JA, Plaza J, Pons-Estel GJ, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009;32:240–5.CrossRefPubMed
33.
Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.CrossRefPubMed
34.
Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205–9.CrossRefPubMedPubMedCentral
35.
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568–76.CrossRefPubMed
36.
Asherson RA, Cervera R, Klumb E, Stojanovic L, Sarzi-Puttini P, Yinh J, et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum. 2008;38:124–31.CrossRefPubMed
37.
Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:530–3.CrossRefPubMedPubMedCentral
38.
Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Semin Arthritis Rheum. 2013;42:417–23.CrossRefPubMed
39.
WHOQOL User manual. Geneva.World Health Organization 1998:61–71.
40.
Boers M, Brooks P, Strand V, et al. The OMERACT filter for outcomes measures in rheumatology. J Rheumatol. 1998;25:198–9.PubMed
41.
Geryk LL, Carpenter DM, Blalock SJ, De Vellis RF, Jorda JM. The impact of co-morbidity on HRQL in rheumatoid arthritis and osteoarthritis patients. Clin Exp Rheumatol. 2015;33:366–74.PubMed
42.
Strand V, Singh JA. Improved Health related Quality of Life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2007 Suppl 9:S237-251.
43.
Ware JE, Sherburne CD. The MOS 36-item short form health survey (SF36) I: concept framework and item election. Med Care. 1992;30:473–83.CrossRefPubMed
44.
Euro-Qol A new facility for the measurement of health-related quality of life. Te EuroQol group. Health policy 1990;16:199–208.
45.
Picavet HSJ, Hoeymans. Health related quality of life in multiple musculoskeletal diseases: SF36 and EQ-ED in the DMC3 study. Annals Rheum Dis. 2004;63:723–729.
46.
Use of sort form SF36 for health status in British patients with RA. Reliability, validity and responsiveness of the sort form 36-item health survey. Br J Rheumatol 1998;37:425–436.
47.
Ware JE. SF-36 health survey update. Lincoln: Quality-Metric Incorporated; 2007.
48.
49.
Wang C, Mayo N, Fortin P. The relationship between related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001;28:3.
50.•
García-Carrasco M, Mendoza-Pinto C, Cardiel MH, Méndez-Martínez S, García-Villaseñor A, Jiménez-Hernández C, et al. Health related quality of life in mexican women with systemic lupus erythematosus: a descriptive study using SF36 and LupusQol. Lupus. 2012;21:1219–24. This descriptive study evaluated HRQoL in a large group of Mexican SLE patients.CrossRefPubMed
51.
Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus an update. Ann Acad Med Singap. 2007;36:115–22.PubMed
52.•
Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015;13:16. Important review demonstrating differences between thrombosis associated with SLE and, with APS.CrossRefPubMedPubMedCentral
53.
Balitsy AK, Peeva V, Su J, et al. Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2011;38:1017–9.CrossRef
54.•
Mevorach-Zussman N, Bolotin A, Shalev BA, Bilenko N, Mazor M, Bashiri A. Anxiety and deterioration of quality of life factors associated with recurrent miscarriage in an observational study. J Perinat Med. 2012;40:495–501. An important paper describing QoL in cases with recurrent miscarriage, includingAPS patients.PubMed
55.
Mathew S, Cesario S, Symes L. Explaining “unexplainded” perinatal loss. Experiences of women with antiphospholipid syndrome. J Perinat Neonat Nurs. 2008;22:293–301.CrossRef
56.
Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, Khamashta. Efficacy and safety of long-term low molecular weight heparin in patiens with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1652–1654.
57.
Hasan SS, Teh KM, Ahmed SI, Chong DW, Ong HC, Naina B. Quality of life (QoL) and international normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health. 2015;129:954–62.CrossRefPubMed
58.••
Georgopoulou S, Efraimidou S, MacLennan SJ, Ibrahim F, Cox T. Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using SF36. Lupus. 2015;24:174–9. First survey that evaluates population with APS exploring patients qualitative view of their disease.CrossRefPubMed
59.••
Zuily S. Rat AC, Regnault V, Kaminsky P, Mismetti P, Ninet J, Baillet N, Magy-Bertrand N. Pasquali J-L, Lambert M, Pasquier E, Lorcerie B, Lecompte L, Guillemin F, Whal D. and TAC(1)C investigators. Impairment of quality of life in patients with antiphospholipid syndrome. Lupus. 2015;24:1161–1168. Highly recommended survey that compares the quality of life in patients with APS, SLE, and the general population. Cardiovascular comorbidities and thrombosis are considered.
Metadata
Title
Organ Damage and Quality of Life in Antiphospholipid Syndrome
Authors
P. Alba
J. A. Gómez-Puerta
M. V. Goycochea-Robles
M. C. Amigo
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 2/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0556-6

Other articles of this Issue 2/2016

Current Rheumatology Reports 2/2016 Go to the issue

Scleroderma (J Varga, Section Editor)

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Pediatric Rheumatology (S Ozen, Section Editor)

Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases

Antiphospholipid Syndrome (S Zuily, Section Editor)

Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome

Scleroderma (J Varga, Section Editor)

Cellular Therapies in Systemic Sclerosis: Recent Progress

Spondyloarthritis (MA Khan, Section Editor)

Causality of Chlamydiae in Arthritis and Spondyloarthritis: a Plea for Increased Translational Research
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits